Skip to contentS
Sarepta Therapeutics, Inc.
S
SRPTSarepta Therapeutics, Inc. Q2 2026 · 10-Q
Revenue$328.69M$328.69M−35.9% vs Q2 2025 Net Income-$4.89M-$4.89MN/M vs Q2 2025 EPS Diluted-$0.05-$0.05N/M vs Q2 2025 Operating Income$13,291,000−88.5% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sarepta Therapeutics, Inc. · CIK 873303 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$196,515,000−14.4% Margins · derivedOperating margin4.0%−18.5 pt vs Q2 2025
Net margin-1.5%−39.9 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 5, 2026 · 36 d after period end